Relief Reports that NeuroRx has Announced Feasibility Collaboration with TFF Pharmaceuticals
Geneva, Switzerland, March 15, 2021 - RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) ("Relief" or the "Company"), a biopharmaceutical company with its lead compound RLF-100(TM) (aviptadil) in advanced clinical development, announces that its partner, NeuroRx, Inc., has reported that work is underway to determine the feasibility of formulating RLF-100(TM) as a dry powder using TFF Pharmaceuticals' Thin-Film Freezing (TFF) technology.
Typically, the TFF process produces high-potency powders that require minimal inactive ingredients, a benefit to drug delivery. Encapsulated TFF powders in dry powder inhalers (DPIs) exhibit aerodynamic properties that enable as much as 75% of the drug to be deposited into the deep lung. Furthermore, a drug that is converted into a powder by the TFF process can be shipped at room temperature and reconstituted at the point of administration, eliminating cold chain requirements.
Chris Stijnen, Chief Commercial Officer of Relief commented: "We are pleased with this initiative to identify an optimal, long-term stable formulation of aviptadil in a dry powder form, which could enable improved delivery of the inhaled product candidate into the lungs."
The relevant NeuroRx press release can be found here.